NASDAQ:PASG Passage Bio Q2 2026 Earnings Report $4.10 -0.02 (-0.49%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Passage Bio EPS ResultsActual EPS-$2.44Consensus EPS -$2.44Beat/MissMet ExpectationsOne Year Ago EPSN/APassage Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APassage Bio Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETUpcoming EarningsPassage Bio's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Passage Bio Earnings HeadlinesPassage Bio Amends Remix Merger, Private Financing TermsSeptember 3, 2026 | tipranks.comPassage Bio, Inc. (PASG) M&A Call Prepared Remarks TranscriptJune 25, 2026 | seekingalpha.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 5 at 1:00 AM | Reagan Gold Group (Ad)PASG stock slumps 16% after-hours — what’s driving the selloff?June 24, 2026 | msn.comPassage Bio and Remix Therapeutics Announce Merger AgreementJune 24, 2026 | markets.businessinsider.comPassage Bio and Remix Therapeutics Announce Merger AgreementJune 24, 2026 | globenewswire.comSee More Passage Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Passage Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Passage Bio and other key companies, straight to your email. Email Address About Passage BioPassage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases of the central nervous system. The company uses adeno-associated virus (AAV) gene therapy platforms to deliver functional genes to target cells, with the goal of addressing the underlying causes of inherited neurological disorders. Passage Bio’s development programs have included investigational therapies for conditions such as GM1 gangliosidosis, Krabbe disease and frontotemporal dementia. Its research and development activities have been supported by collaborations with the University of Pennsylvania’s Gene Therapy Program, which has contributed expertise in vector design, manufacturing and clinical development. As with other clinical-stage biotechnology companies, its product candidates remain subject to clinical testing and regulatory review and may not receive approval. Founded in 2018 and headquartered in Philadelphia, Passage Bio has primarily served patients and research markets through its global clinical-development and biotechnology activities rather than through commercialized products. The company became publicly traded on the Nasdaq under the symbol PASG in 2020. Its programs, partnerships and corporate strategy may evolve as clinical data and regulatory developments become available.View Passage Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
